Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00087997 · ClinicalTrials.gov registry record · Phase 2

A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas

A Phase 2 study, sponsored by Synta Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
80
Enrollment target

NCT00087997: Completed Phase 2 study, sponsored by Synta Pharmaceuticals.

NCT00087997 is a Phase 2 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00087997, a Phase 2 study, has completed, sponsored by Synta Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
80 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of an experimental study drug (STA-4783) combined with an approved cancer medicine, paclitaxel, in the treatment of soft tissue sarcomas. Paclitaxel (Taxol®) has been approved and used in the United States since 1992.

Interventions

  • DRUG STA-4783

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2004-07
Est. Completion 2005-10
Phase Phase 2
Synta Pharmaceuticals

21 total trials

What the finished NCT00087997 record still lists

NCT00087997 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).

The record links to 0 conditions, and to 1 intervention - of which STA-4783 is the first listed.

NCT00087997 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00087997 about?

NCT00087997 is a clinical study titled "A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas". The purpose of this study is to evaluate the safety and effectiveness of an experimental study drug (STA-4783) combined with an approved cancer medicine, paclitaxel, in the treatment of soft tissue sarcomas. Paclitaxel (Taxol®) has been approved and used in the United States since 1992.

What is the current status of trial NCT00087997?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2004-07. Estimated completion is 2005-10.

What interventions are being tested in trial NCT00087997?

The interventions under investigation include: STA-4783 (DRUG).

Who is sponsoring clinical trial NCT00087997?

This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00087997's enrollment target sits among peer trials

80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00087997, the US trial registry maintained by the National Library of Medicine. NCT00087997 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.